Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Valar Labs has announced the successful completion of a $22 million Series A funding round, co-led by DCVC and a16z, with participation from Pear VC. The biotech startup has developed an AI-powered diagnostic tool, Vesta, which predicts treatment responses for bladder cancer patients. This tool, based on computational histology, aims to reduce uncertainty in cancer treatment decisions and is already in commercial use for bladder cancer. Valar Labs plans to expand its application to other types of cancer. The technology has been highlighted in a Nature story, and the company aims to translate this tech to clinical settings, potentially saving precious time for patients. There are roughly 2 million new cancer diagnoses annually in the US alone.
Valar Labs, which has developed AI models to help predict bladder cancer treatment outcomes, raised a $22M Series A led by DCVC and a16z (Devin Coldewey / TechCrunch) https://t.co/N0uHyZegwr 📫 Subscribe: https://t.co/OyWeKSRpIM https://t.co/mvSKT4fnKL
We @a16z are thrilled to announce our Series A investment in @valarlabs, which is building AI tools to assist oncologists in cancer treatment decisions. There are roughly 2 million new cancer diagnoses annually in the US alone. Each diagnosis involves a biopsy of the patient's… https://t.co/xeQ5zTTOpQ
Excited to announce @DCVC’s investment in @valarlabs Valar’s “computational histology” platform provides prognosis and tx response prediction for cancer patients Already commercial in bladder cancer, excited to see this team expand to new indications! https://t.co/Fiwgpd1ALO
